Factors associated with the choice of the first biologic in psoriasis: real‐life analysis from the Psobioteq cohort

Abstract

We identified patient- and disease-related factors that have important influence on the choice of the first biological agent in clinical practice. Clinicians appear to have a holistic approach to patient characteristics when choosing a biological agent in psoriasis.

Psoriasis Area and Severity Index response in moderate‐severe psoriatic patients switched to adalimumab: results from the OPPSA study

“…Variability in treatment efficacy of adalimumab has been observed among these controlled and real-life studies, and causal factors have already been identified. 22,[28][29][30][31][32] While no difference was observed in terms of PASI response between biologic na€ ıve, previous anti-TNF-alpha or previous ustekinumab treatment on the effect of adalimumab, stepwise logistic regression in our study revealed that younger patients, no diabetes/metabolic syndrome, no dyslipidemia, no hypertension or a lower PASI at baseline were significantly associated with better achievement of PASI response by 3 and 6 months. Interestingly, at later time points (1, 2 and 3 years), absence of hypertension and a positive diagnosis for psoriasis/psoriatic arthritis were significantly associated with increased odds of achieving PASI 90 and complete remission (PASI 100).…”

Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis

“…Moreover, in concordance with previous studies in adult psoriasis, adalimumab was received more frequently in patients with severe psoriasis than were etanercept or ustekinumab. 25 No association was found between psoriatic arthritis and the choice of biological therapy. The most commonly prescribed biological agent in our study was etanercept, whereas Sbidian et al 25 reported that adalimumab was the most commonly prescribed agent in adult psoriasis.…”

“…25 No association was found between psoriatic arthritis and the choice of biological therapy. The most commonly prescribed biological agent in our study was etanercept, whereas Sbidian et al 25 reported that adalimumab was the most commonly prescribed agent in adult psoriasis. This difference between the two studies can be explained by the fact that etanercept was the first biological agent to be approved in children in 2008.…”

“…In our study, SAEs were not rare and were similar to those found in adults on biological therapy. [25][26][27] Data on the safety of biological agents in paediatric psoriasis are scarce, with much of the safety data being taken from the studies of their use for other indications in this age group, such as juvenile idiopathic arthritis and Crohn's disease. However, side-effect profiles and the safety of biological agents in paediatric psoriasis have been reported in a small number of studies.…”

“…Service de Dermatologie, Centre Hospitalier Universitaire de Brest, Brest, France 11 Service de Dermatologie, Centre Hospitalier Universitaire Pontchaillou, Universit e de Rennes, Rennes, France 12 Service de Dermatologie, V en er eologie et Canc erologie Cutan ee, Hôpital de la Timone, Assistance-publique-Hôpitaux de Marseille, Marseille, France 13 Service de P ediatrie, Hôpital Femme-M ere-Enfant, Hospices Civils de Lyon, Bron, France 14 Service de Dermatologie, Hôpital Archet 2, ESPIC CHU-Lenval, Nice, France 15 Service de P ediatrie G en erale, Hôpital Robert Debr e, Assistance Publique-Hôpitaux de Paris, Paris, France 16 Service de Dermatologie, Hôpital Sud, Amiens, France 17 Service de Rhumatologie P ediatrique, Hôpital Femme-M ere-Enfant, Hospices Civils de Lyon, Bron, France 18 Service de Dermatologie, Centre Hospitalier de Cornuaille, Quimper, France 19 Service de Dermatologie, Unit e de Dermatologie P ediatrique, Centre Hospitalier Universitaire de Tours, Universit e de Tours, Tours, France 20 Service de Rhumatologie P ediatrique, Centre Hospitalier Universitaire Bicêtre, Universit e Paris Sud-Saclay, UVSQ, Assistance Publique-Hôpitaux de Paris HP, Le Kremlin Bicêtre, France 21 Service de Dermatologie, Hôpital d'Instruction des Arm ees B egin, Saint Mand e, France 22 Service de Dermatologie, Hôpital de Niort, Niort, France 23 Service de Dermatologie, Centre Hospitalier Universitaire Charles-Nicolle, Rouen, France 24 Service de Dermatologie, Hôpital d'Auxerre, Auxerre, France 25 Service de Dermatologie, Centre Hospitalier Universitaire d'Angers, Angers, France 26 Service…”